The COXEN Principle: Translating Signatures of In vitro Chemosensitivity into Tools for Clinical Outcome Prediction and Drug Discovery in Cancer
- 28 February 2010
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (5), 1753-1758
- https://doi.org/10.1158/0008-5472.can-09-3562
Abstract
Substantial effort has been devoted to in vitro testing of candidate chemotherapeutic agents. In particular, the United States National Cancer Institute Developmental Therapeutics Program (NCI-DTP) Human Tumor Cell Line Screen has screened hundreds of thousands of compounds and extracts, for which data on more than 40,000 compounds tested on a panel of 60 cancer cell lines (NCI-60) are publically available. In tandem, gene expression profiling has brought about a sea change in our understanding of cancer biology, allowing discovery of biomarkers or signatures able to characterize, classify, and prognosticate clinical behavior of human tumors. Recent studies have used tumor profiling matched to clinical trial outcome data to derive gene expression models predicting therapeutic outcomes, though such efforts are costly, time-consuming, tumor type-specific, and not amenable to rare diseases. Furthermore, addition of new or established drugs to multidrug combinations in which such models are already available requires the entire model to be re-derived. Can the aforementioned in vitro testing platform, coupled to the universal language of genomics, be used to develop, a priori, gene expression models predictive of clinical outcomes? Recent advances, including the CO-eXpression ExtrapolatioN (COXEN) algorithm, suggest that development of these models may be possible and raise important implications for future trial design and drug discovery. Cancer Res; 70(5); 1753–8Keywords
This publication has 29 references indexed in Scilit:
- Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumoursEuropean Journal of Cancer, 2010
- Concordant Gene Expression Signatures Predict Clinical Outcomes of Cancer Patients Undergoing Systemic TherapyCancer Research, 2009
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 2009
- Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladderCancer, 2009
- A strategy for predicting the chemosensitivity of human cancers and its application to drug discoveryProceedings of the National Academy of Sciences of the United States of America, 2007
- Validation study of the prediction system for clinical response of M‐VAC neoadjuvant chemotherapyCancer Science, 2006
- Genomic signatures to guide the use of chemotherapeuticsNature Medicine, 2006
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Robust classification modeling on microarray data using misclassification penalized posteriorBioinformatics, 2005
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002